OSR Health Exercises $15M Equity Option, Swaps Cash Purchase for Staged Convertible Notes
OSRH has more than doubled off its 52-week low of $0.075.
Summary
OSR Health exercised its full $15 million equity option under the VXM01 license agreement with BCME, but instead of selling stock for cash it will issue up to $15 million of convertible notes to a third-party buyer arranged by BCME. A Korea-based investor is in talks to buy the notes, which would fund in tranches tied to milestones, with closing targeted by December 31, 2026. Nothing is signed yet: a definitive note agreement still has to be negotiated, and if the purchase misses the closing date by ten business days the election is withdrawn and the equity option reinstated. The cash matters because the Q2 10-Q showed only $1.5 million on hand, a 72% revenue decline and unremediated material weaknesses, and the company is still working through its Nasdaq delisting appeal filed in August. Conversion terms are undisclosed, so dilution from the notes is unknown; the August shareholder vote already raised authorized shares to 250 million. Management also flagged ongoing reverse-takeover talks for OSRK, an OTCQB uplisting application and a VXM01 manuscript due by end-2026.
At the time of this announcement, OSRH was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.08 to $0.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.